South Korea
· Delayed Price · Currency is KRW S.Biomedics Statistics
Total Valuation
S.Biomedics has a market cap or net worth of KRW 192.63 billion. The enterprise value is 196.22 billion.
| Market Cap | 192.63B |
| Enterprise Value | 196.22B |
Important Dates
The next estimated earnings date is Friday, March 21, 2025.
| Earnings Date | Mar 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
S.Biomedics has 11.75 million shares outstanding. The number of shares has increased by 7.04% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 11.75M |
| Shares Change (YoY) | +7.04% |
| Shares Change (QoQ) | +0.52% |
| Owned by Insiders (%) | 21.49% |
| Owned by Institutions (%) | 5.01% |
| Float | 8.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.36 |
| PB Ratio | 18.43 |
| P/TBV Ratio | 18.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -50.80 |
| EV / Sales | 15.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -38.31 |
Financial Position
The company has a current ratio of 2.75, with a Debt / Equity ratio of 0.69.
| Current Ratio | 2.75 |
| Quick Ratio | 2.23 |
| Debt / Equity | 0.69 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.23 |
| Interest Coverage | -6.59 |
Financial Efficiency
Return on equity (ROE) is -19.00% and return on invested capital (ROIC) is -13.33%.
| Return on Equity (ROE) | -19.00% |
| Return on Assets (ROA) | -10.37% |
| Return on Capital (ROIC) | -13.33% |
| Revenue Per Employee | 245.71M |
| Profits Per Employee | -72.87M |
| Employee Count | 53 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 2.30 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +84.87% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +84.87% |
| 50-Day Moving Average | 24,848.40 |
| 200-Day Moving Average | 28,929.00 |
| Relative Strength Index (RSI) | 35.95 |
| Average Volume (20 Days) | 153,662 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, S.Biomedics had revenue of KRW 13.02 billion and -3.86 billion in losses. Loss per share was -338.94.
| Revenue | 13.02B |
| Gross Profit | 6.64B |
| Operating Income | -5.82B |
| Pretax Income | -3.00B |
| Net Income | -3.86B |
| EBITDA | -4.15B |
| EBIT | -5.82B |
| Loss Per Share | -338.94 |
Balance Sheet
The company has 13.87 billion in cash and 11.43 billion in debt, giving a net cash position of 2.44 billion or 207.76 per share.
| Cash & Cash Equivalents | 13.87B |
| Total Debt | 11.43B |
| Net Cash | 2.44B |
| Net Cash Per Share | 207.76 |
| Equity (Book Value) | 16.48B |
| Book Value Per Share | 889.82 |
| Working Capital | 12.12B |
Cash Flow
In the last 12 months, operating cash flow was -3.97 billion and capital expenditures -1.16 billion, giving a free cash flow of -5.12 billion.
| Operating Cash Flow | -3.97B |
| Capital Expenditures | -1.16B |
| Free Cash Flow | -5.12B |
| FCF Per Share | -436.04 |
Margins
Gross margin is 51.01%, with operating and profit margins of -44.73% and -29.66%.
| Gross Margin | 51.01% |
| Operating Margin | -44.73% |
| Pretax Margin | -23.01% |
| Profit Margin | -29.66% |
| EBITDA Margin | -31.84% |
| EBIT Margin | -44.73% |
| FCF Margin | n/a |
Dividends & Yields
S.Biomedics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.04% |
| Shareholder Yield | -7.04% |
| Earnings Yield | -2.07% |
| FCF Yield | -2.66% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
S.Biomedics has an Altman Z-Score of 5.29.
| Altman Z-Score | 5.29 |
| Piotroski F-Score | n/a |